Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis
- PMID: 32558987
- PMCID: PMC7754428
- DOI: 10.1111/1471-0528.16366
Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis
Abstract
Background: The efficacy of hormonal regimens for the prevention of endometrioma recurrence in women who have undergone conservative surgery is still controversial.
Objective: To compare the efficacy of different hormonal regimens in this context and to rank them.
Search strategy: MEDLINE and Scopus databases were searched through January 2020.
Selection criteria: Randomised controlled trials (RCTs) or cohorts, comparing the effect of any pair of interventions (i.e. cyclic oral contraceptives [OC], continuous OC, gonadotropin-releasing hormone agonist [GnRHa], dienogest [DNG], levonorgestrel-releasing intrauterine system [LNG-IUS] and expectant management) on endometrioma recurrence were selected.
Data collection and analysis: Data were independently extracted by two reviewers. Relative treatment effects were estimated using network meta-analysis (NMA) and ranked in descending order.
Main results: Six RCTs (675 patients) and 16 cohorts (3089 patients) were included. NMA of the RCTs involving expectant management, cyclic OC, continuous OC, GnRHa and GnRHa + LNG-IUS, showed that all hormonal regimens had a nonsignificant lower risk of endometrioma recurrence compared with expectant management. NMA of the cohorts involving expectant, cyclic OC, continuous OC, GnRHa, DNG, LNG-IUS, GnRHa + OC, and GnRHa + LNG-IUS indicated that LNG-IUS, DNG, continuous OC, GnRHa + OC and cyclic OC had a significantly lower risk of endometrioma recurrence than expectant management. LNG-IUS was ranked highest, followed by DNG and GnRHa + LNG-IUS. Long-term use of hormonal treatment either OC or progestin had a significantly lower risk of endometrioma recurrence than expectant treatment.
Conclusion: In the NMA of RCTs, there was no evidence supporting hormonal treatment for postoperative prevention of endometrioma recurrence. This was at odds with the cohort evidence, which found the protective effect of OC and progestin regimens, especially long-term treatment. Large-scale RCTs of these agents are still required.
Tweetable abstract: Hormonal regimens given as long-term treatment tend to reduce risk of endometrioma recurrence after conservative surgery.
Keywords: Endometrioma; hormonal treatment; network meta-analysis; ovarian cystectomy; recurrence.
© 2020 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.
Comment in
-
Postoperative medical therapies for the prevention of endometrioma recurrence - do we now have the final answer?BJOG. 2021 Jan;128(1):36. doi: 10.1111/1471-0528.16415. Epub 2020 Aug 10. BJOG. 2021. PMID: 32659035 No abstract available.
-
Deciding on the appropriate pharmacotherapy for the treatment of endometriosis.Expert Opin Pharmacother. 2023 Jan;24(1):1-5. doi: 10.1080/14656566.2022.2113383. Epub 2022 Aug 18. Expert Opin Pharmacother. 2023. PMID: 35973977 No abstract available.
References
-
- Liu X, Yuan L, Shen F, Zhu Z, Jiang H, Guo SW. Patterns of and risk factors for recurrence in women with ovarian endometriomas. Obstet Gynecol 2007;109:1411–20. - PubMed
-
- Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ 2014;348:g1752. - PubMed
-
- Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol 2014;10:261–75. - PubMed
-
- Somigliana E, Berlanda N, Benaglia L, Vigano P, Vercellini P, Fedele L. Surgical excision of endometriomas and ovarian reserve: a systematic review on serum antimullerian hormone level modifications. Fertil Steril 2012;98:1531–8. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
